Zobrazeno 241 - 250
of 269
pro vyhledávání: '"David F. Claxton"'
Autor:
Issa F. Khouri, Soon Pal Suh, Albert B. Deisseroth, Hagop M. Kantarjian, Debra Ellerson, Marc Etkin, David F. Claxton, Malcolm K. Brenner, Marylynne Filaccio, Moshe Talpaz, Kateri A. Moore, John W. Belmont, Robert C. Moen, Christopher L. Reading, Eugenia Gaozza, A. M. Moseley
Publikováno v:
Scopus-Elsevier
Marrow cells were exposed to the LNL6 or G1N safety-modified variants of the N2 retrovirus, which contain the G418 bacterial resistance gene neo. The frequency of acquisition of the G418 resistance phenotype following exposure to LNL6 or G1N was comp
Autor:
Stefan Faderl, Stephen Eckert, Roger M. Lyons, Harry P. Erba, Janice Gabrilove, Martha Arellano, David F. Claxton, Tibor Kovacsovics, Dirk Huebner, Hagop M. Kantarjian
Publikováno v:
Blood. 114:2083-2083
Abstract 2083 Poster Board II-60 Background: Outcomes in older patients with AML have not improved in several decades. Response rates decline and treatment related mortality increases with advancing age [Appelbaum, Blood 2006]. Older adults have a hi
G-CSF Mobilized Versus Conventional Donor Lymphocytes in the Treatment of Hematological Malignancies
Autor:
Giampaolo Talamo, David F. Claxton, Kamal Kant Singh Abbi, Kenneth G. Lucas, Michelle Carraher, W. Chritopher Ehmann, Witold B. Rybka
Publikováno v:
Blood. 114:4301-4301
Abstract 4301 Introduction Donor lymphocyte infusions (DLI) can reverse relapse of hematologic malignancy following allogeneic hematopoietic stem cell transplant (HSCT) in some cases. G-CSF is used to mobilize progenitor cells for transplantation and
Autor:
Giampaolo Talamo, Michelle Carraher, Witold B. Rybka, W. Christopher Ehmann, Hong Zheng, Eric W. Schaefer, David F. Claxton
Publikováno v:
Blood. 114:4329-4329
Abstract 4329 The use of sirolimus (rapamycin) as an immunosuppressive agent after allogeneic hematopoietic transplantation is appealing given its antitumor and tolerance-inducing properties. Its safety and efficacy have been studied but are not comp
Autor:
Janice Gabrilove, Thomas J. Myers, Hagop M. Kantarjian, Roger M. Lyons, Martha Arellano, Tibor Kovacsovics, Stefan Faderl, Clay R Warnock, Harry P. Erba, David F. Claxton
Publikováno v:
Blood. 114:4162-4162
Abstract 4162 Introduction The CLASSIC II trial previously reported an overall remission rate of 46% (38% complete remission [CR] and 8% CR with incomplete platelet recovery [CRp]), median duration of remission 56 weeks, median disease-free survival
Autor:
Janice Gabrilove, Martha Arellano, Stefan Faderl, Hagop M. Kantarjian, Tibor Kovacsovics, Roger M. Lyons, David F. Claxton, Elizabeth Anderson, Harry P. Erba, Elly Barry
Publikováno v:
Blood. 114:4155-4155
Abstract 4155 Background Clofarabine has produced overall remission rates of 46% (38% complete remission, 8% complete remission with incomplete platelet recovery), manageable toxicity, and 30 and 60 day mortality of 10% and 16%, respectively, in pati
Autor:
Roger M. Lyons, Martha Arellano, David F. Claxton, Stefan Faderl, Janice Gabrilove, Dirk Huebner, Stephen Eckert, Harry P. Erba, Hagop M. Kantarjian, Tibor Kovacsovics
Publikováno v:
Blood. 114:2061-2061
Abstract 2061 Poster Board II-38 Background: We have previously reported efficacy and safety of clofarabine in patients = 60 with at least one unfavorable prognostic factor. Retrospective analyses have suggested that survival in AML is related to qua
Autor:
Witold B. Rybka, David F. Claxton, W. Chritopher Ehmann, Giampaolo Talamo, Eric W. Schaefer, Jon Karch, Michelle Carraher
Publikováno v:
Blood. 114:1212-1212
Abstract 1212 Poster Board I-234 Background: The use of sirolimus (rapamycin) as primary immunosuppression for allogeneic blood and marrow transplantation is logical given its favorable anti-tumor and tolerance inducing properties. Methods: After IRB
Autor:
Sulfi Ibrahim, David F. Claxton
Publikováno v:
Cancer Biology & Therapy. 8:1101-1101
Commentary to:Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignanciesAnthony Mato, Selina Luger, Daniel F. Heitjan, Rosemarie Mick, Scott D.
Autor:
Witold B. Rybka, W. C. Ehmann, Joseph Mierski, Giampaolo Talamo, S. Ibrahin, David F. Claxton
Publikováno v:
Journal of Clinical Oncology. 27:7096-7096
7096 Background: The combination of dexamethasone and lenalidomide is currently considered one of the standards of care for induction therapy of patients with multiple myeloma (MM) before autologous stem cell transplantation (ASCT). Increasing eviden